Tag: tumor embolization devices market growth

  • Tumor Embolization Devices Market Outlook Through 2030: Understanding The Growth Opportunity

    Tumor Embolization Devices Market Outlook Through 2030: Understanding The Growth Opportunity

    Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

    Tumor Embolization Devices Market Growth Potential: How Will Market Size Shift Through 2030?

    The market size for tumor embolization devices has seen strong expansion in recent years. It is projected to increase from $1587.48 billion in 2025 to $1732.02 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. This historic growth can be attributed to the broader application of interventional oncology practices, a rise in the incidence of solid tumors, the growing acceptance of minimally invasive procedures, the development of advanced catheter technologies, and the expanding utilization of embolization in cancer treatment.

    The tumor embolization devices market is projected to experience robust expansion over the coming years. This market is set to reach $2464.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. This anticipated growth is driven by factors such as increased investments in interventional oncology, a heightened demand for combination cancer therapies, the widening scope of targeted drug delivery techniques, an increasing emphasis on organ-sparing treatments, and the greater integration of imaging-guided interventions. Key developments expected during this period involve the rising adoption of targeted embolization therapies, a surge in demand for drug-eluting embolic agents, the expanding application of image-guided embolization procedures, a broadening of minimally invasive oncology interventions, and a stronger focus on precise tumor targeting.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=42769714&type=smp&name=Tumor%20Embolization%20Devices%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Tumor Embolization Devices Market Growth Drivers: What’s Behind The Acceleration?

    The global increase in cancer diagnoses is expected to fuel the expansion of the Tumor Embolization Devices Market throughout the forecast period. Cancer is characterized by the uncontrolled proliferation of abnormal cells, which can spread within the body. This surge in cancer cases is primarily influenced by aging demographics, as older individuals face a greater likelihood of developing cancer due to accumulated genetic mutations and prolonged exposure to various risk factors. Tumor embolization devices play a crucial role in managing this rising incidence by offering a precise, minimally invasive treatment that restricts blood supply to tumors, thereby hindering their growth and enhancing patient recovery. For example, in 2023, the American Cancer Society Inc., a US-based non-profit health organization, reported 1,958,310 new cancer diagnoses in the US, which represents an increase from the over 1,918,030 new cases recorded in 2022. Consequently, the escalating global cancer incidence rate is projected to significantly elevate the demand within the tumor embolization market in the coming years.

    Tumor Embolization Devices Market Segment Trends And Revenue Contributors

    The tumor embolization devices market covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    Tumor Embolization Devices Market Trends: What’s Defining The Industry’s Next Phase?

    Major companies within the tumor embolization devices market are intensifying their efforts to introduce innovative medications, such as Eye90, in order to maximize their market revenue. Eye90 microspheres function as a Y90 radioembolization device specifically engineered for treating liver tumors, particularly hepatocellular carcinoma. For example, in May 2023, ABK Biomedical, a Canada-based medical device company, obtained Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to initiate a multicenter pivotal study involving Eye90 microspheres for hepatocellular carcinoma. Eye90 microspheres represent a novel Y90 radioembolization technology, manufactured through a proprietary process that yields microspheres with a uniform size distribution and high radioactivity concentration. The design of these microspheres is intended to deliver a significant radiation dose to the tumor while minimizing exposure to healthy tissue.

    Tumor Embolization Devices Market Leading Companies And Competitive Benchmarking

    Major companies operating in the tumor embolization devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., Varian Medical Systems Inc.

    View The Full Tumor Embolization Devices Market Report:

    https://thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Tumor Embolization Devices Market Top Region By Revenue And Market Share

    North America was the largest region in the tumor embolization devices market in 2025. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Tumor Embolization Devices Market Expected To Reach $2464.51 Billion By 2030 As Growth Accelerates At 9.2% CAGR

    Tumor Embolization Devices Market Expected To Reach $2464.51 Billion By 2030 As Growth Accelerates At 9.2% CAGR

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    The tumor embolization devices market has witnessed significant growth recently, driven by advancements in cancer treatment and increasing prevalence of tumors worldwide. With continued innovations and rising healthcare investments, this sector is set to expand further, offering promising opportunities for improved, minimally invasive cancer therapies. Let’s explore the current state, key growth factors, market segmentation, recent technological progress, leading companies, and regional dynamics shaping this market.

    Strong Growth in Tumor Embolization Devices Market Size and Forecast

    The tumor embolization devices market has seen robust expansion over recent years. It is projected to grow from $1587.48 billion in 2025 to $1732.02 billion in 2026, at a compound annual growth rate (CAGR) of 9.1%. This growth reflects increased adoption of interventional oncology procedures, a rising number of solid tumor cases, and enhanced catheter technologies. Looking ahead, the market is expected to reach $2464.52 billion by 2030, growing at a CAGR of 9.2%. Factors supporting this forecast include greater investments in interventional oncology, growing demand for combination therapies, advancements in targeted drug delivery, and a stronger emphasis on organ-preserving treatments. Additionally, the integration of imaging-guided interventions and the rise of minimally invasive oncology methods are key trends fueling market expansion.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp

    The Rising Burden of Cancer as a Market Driver

    One of the primary factors propelling the tumor embolization devices market is the increasing global incidence of cancer. Cancer, characterized by uncontrolled cell growth with potential to spread throughout the body, is becoming more common, especially among aging populations. Older individuals face a higher risk due to accumulated genetic changes and prolonged exposure to carcinogens. Tumor embolization devices provide targeted treatments by blocking the blood supply to tumors, slowing their progression and improving patient outcomes. For example, in 2023, the American Cancer Society reported 1,958,310 new cancer cases diagnosed in the United States, surpassing the 1,918,030 cases recorded in 2022. This upward trend in cancer diagnoses worldwide is expected to drive demand for embolization devices in the years ahead.

    Increasing Healthcare Spending as a Growth Catalyst

    Rising healthcare expenditures are playing a crucial role in advancing the tumor embolization devices market. Healthcare spending covers various services, including preventive care, emergency assistance, and nutrition programs, all of which contribute to better health infrastructure and product development. For instance, a May 2023 report from the UK’s Office for National Statistics indicated that healthcare spending in the UK grew by 5.6% between 2022 and 2023, reaching approximately $317.63 billion (£292 billion). This increased financial commitment to healthcare enables the development and wider adoption of tumor embolization technologies, thereby supporting market growth.

    Access The Complete Tumor Embolization Devices Market Report:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    How the Tumor Embolization Devices Market is Organized by Key Categories

    The tumor embolization devices market is segmented across several important categories:

    1) By Type: Radioembolic Agents and Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors and Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, and Surgical Centers

    Further breakdown includes:

    – Radioembolic Agents such as Yttrium-90 (Y-90) Microspheres and Holmium-166 Microspheres

    – Non-radioactive Embolic Agents including Drug-Eluting Beads (DEBs), Polyvinyl Alcohol (PVA) Microspheres, Gelatin Sponges, and Liquid Embolic Agents like Onyx and glue-based products

    This structured segmentation helps pinpoint specific areas of growth and innovation within the market.

    Innovations and Technological Advances Driving Market Transformation

    Leading companies in this market are focusing heavily on developing novel therapies and devices to enhance treatment effectiveness. One notable example is Eye90 microspheres, a Y90 radioembolization product designed to treat liver tumors, particularly hepatocellular carcinoma. In May 2023, ABK Biomedical, a Canadian medical device company, received FDA approval to begin a multicenter pivotal trial for Eye90 microspheres. This technology features a proprietary manufacturing process that produces microspheres with uniform size and high radioactivity concentration, enabling targeted radiation delivery to tumors while minimizing damage to healthy tissues. Such innovations are reshaping treatment options and expanding the utility of tumor embolization devices.

    Leading Players Shaping the Tumor Embolization Devices Market

    The competitive landscape of the tumor embolization devices market is dominated by several prominent companies, including Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., and Varian Medical Systems Inc. These firms are continuously investing in research and development to maintain market leadership.

    Regional Insights Highlighting Market Leaders and Growth Areas

    In 2025, North America held the largest share in the tumor embolization devices market, reflecting the region’s advanced healthcare infrastructure and high adoption rates of interventional oncology techniques. Asia-Pacific followed as the second-largest market, benefiting from expanding healthcare access and growing cancer prevalence. The report also covers other key regions, including South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive view of the global market landscape.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Tumor Embolization Devices Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

    Tumor Embolization Devices Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Much Will The Market Value Of The Tumor Embolization Devices Market Grow Between 2026 And 2030?

    The tumor embolization devices market size has experienced significant growth in recent years. It is anticipated to increase from $1587.48 billion in 2025 to $1732.02 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. This historical growth can be linked to factors such as the expansion of interventional oncology practices, a rising prevalence of solid tumors, the increasing adoption of minimally invasive procedures, the availability of advanced catheter technologies, and the growing application of embolization in cancer treatment.

    The tumor embolization devices market size is projected to undergo significant expansion over the next few years. It is expected to reach $2464.52 billion by 2030, advancing at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth within this forecast period stems from several factors, including increasing investments in interventional oncology, a growing demand for combination cancer therapies, the broadening of targeted drug delivery techniques, an increasing emphasis on organ-sparing treatments, and the greater integration of imaging-guided interventions. Prominent trends for the forecast period feature the rising adoption of targeted embolization therapies, an escalating demand for drug-eluting embolic agents, the expanding utilization of image-guided embolization procedures, the proliferation of minimally invasive oncology interventions, and an intensified focus on precision tumor targeting.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    What Significant Factors Are Influencing The Tumor Embolization Devices Market Expansion?

    The worldwide increase in cancer diagnoses is anticipated to contribute to the growth of the tumor embolization devices market during the forecast period. Cancer is a condition where abnormal cells multiply uncontrollably and have the potential to invade or spread to other parts of the body. The rising incidence of cancer cases is influenced by aging populations, as older individuals are more susceptible to developing cancer due to accumulated genetic mutations and extended exposure to various risk factors. Tumor embolization devices are instrumental in addressing the surge in cancer cases by offering a targeted, minimally invasive treatment that restricts blood flow to tumors, effectively slowing their progression and improving patient outcomes. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1,958,310 new cancer cases were diagnosed in the US, indicating an increase compared to more than 1,918,030 new cancer cases in 2022. Therefore, the escalating global cancer incidence rate is projected to stimulate demand for the tumor embolization market in the forthcoming years.

    Which Segment Categories Are Included In The Tumor Embolization Devices Market Segment Analysis?

    The tumor embolization devices market covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    What Trends Are Affecting The Direction Of The Tumor Embolization Devices Market?

    Leading companies operating in the tumor embolization devices market are increasingly focusing on introducing innovative medications, such as Eye90, to maximize their revenue within the market. Eye90 microspheres function as a Y90 radioembolization device specifically designed for the management of liver tumors, particularly hepatocellular carcinoma. For instance, in May 2023, ABK Biomedical, a Canada-based medical device firm, secured Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin a multicenter pivotal study of Eye90 microspheres for hepatocellular carcinoma. Eye90 microspheres constitute a new technology for Y90 radioembolization, created using a proprietary manufacturing process that yields microspheres with a uniform size distribution and high radioactivity concentration. The design of these microspheres aims to deliver a significant radiation dose to the tumor while simultaneously minimizing exposure to healthy tissue.

    Who Are The Active Companies Shaping The Tumor Embolization Devices Market?

    Major companies operating in the tumor embolization devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., Varian Medical Systems Inc.

    Get The Full Tumor Embolization Devices Market Report:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    Which Region Leads The Tumor Embolization Devices Market In Terms Of Market Share?

    North America was the largest region in the tumor embolization devices market in 2025. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Tumor Embolization Devices Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    Browse Through More Reports Similar to the Global Tumor Embolization Devices Market 2026, By The Business Research Company

    Neurovascular Embolization Devices Market Report 2026

    https://www.thebusinessresearchcompany.com/report/neurovascular-embolization-devices-global-market-report

    Transcatheter Embolization And Occlusion Devices Market Report 2026

    https://www.thebusinessresearchcompany.com/report/transcatheter-embolization-and-occlusion-devices-global-market-report

    Uterine Fibroid Embolization Device Market Report 2026

    https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Tumor Embolization Devices Market Size Outlook and Demand Growth Across 2026–2030

    Tumor Embolization Devices Market Size Outlook and Demand Growth Across 2026–2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Estimated Market Size Of The Tumor Embolization Devices Market During 2026–2030?

    The tumor embolization devices market has shown significant growth in recent years. Its value is projected to rise from $1587.48 billion in 2025 to $1732.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.1%. This historical expansion is credited to factors such as the proliferation of interventional oncology practices, an increased incidence of solid tumors, the greater embrace of minimally invasive procedures, the availability of advanced catheter technologies, and the broadening application of embolization within cancer care.

    The tumor embolization devices market is anticipated to experience substantial expansion over the coming years. Its valuation is projected to reach $2464.52 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 9.2%. This projected growth during the forecast period is attributable to several factors, including escalating investments in interventional oncology, a heightened demand for combination cancer therapies, the broadening of targeted drug delivery techniques, an increasing emphasis on organ-sparing treatments, and the greater integration of imaging-guided interventions. Key trends anticipated during the forecast timeframe encompass the expanding adoption of targeted embolization therapies, an increasing requirement for drug-eluting embolic agents, the wider application of image-guided embolization procedures, the diversification of minimally invasive oncology interventions, and an intensified focus on precise tumor targeting.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp

    What Underlying Factors Are Accelerating The Growth Of The Tumor Embolization Devices Market?

    The global increase in cancer diagnoses is expected to fuel the expansion of the tumor embolization devices market throughout the forecast period. Cancer is characterized by the uncontrolled proliferation of abnormal cells that can infiltrate or metastasize to various bodily regions. This escalation in cancer cases is primarily attributed to aging demographics, given that older individuals face a greater predisposition to cancer owing to accumulated genetic alterations and extended exposure to causative elements. Tumor embolization devices address the growing number of cancer cases by offering a precise, minimally invasive therapeutic option that restricts blood supply to tumors, thereby inhibiting their progression and enhancing patient recovery. For example, the American Cancer Society Inc., a US-based non-profit health organization, reported 1,958,310 new cancer cases diagnosed in the US in 2023, representing an uptick from over 1,918,030 new cases recorded in 2022. Consequently, the escalating global cancer incidence rate is projected to significantly enhance the demand for the tumor embolization market in the coming years.

    How Are The Various Segments Of The Tumor Embolization Devices Market Categorized?

    The tumor embolization devices market covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    What Trends Are Affecting The Expansion Of The Tumor Embolization Devices Market?

    Major companies in the tumor embolization devices market are increasingly focusing on introducing innovative medications, such as Eye90, to maximize their revenue in the sector. Eye90 microspheres represent a Y90 radioembolization device specifically engineered for treating liver tumors, particularly hepatocellular carcinoma. For instance, in May 2023, ABK Biomedical, a medical device company based in Canada, obtained Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to commence a multicenter pivotal study of Eye90 microspheres for hepatocellular carcinoma. Eye90 microspheres are a novel Y90 radioembolization technology created using a proprietary manufacturing process that yields microspheres with uniform size distribution and high radioactivity concentration. These microspheres are designed to deliver a significant radiation dose to the tumor while minimizing exposure to healthy tissue.

    Which Major Firms Influence Developments In The Tumor Embolization Devices Market?

    Major companies operating in the tumor embolization devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., Varian Medical Systems Inc.

    Read the full tumor embolization devices market report here:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    Which Region Is Projected To Dominate The Tumor Embolization Devices Market During The Forecast Period?

    North America was the largest region in the tumor embolization devices market in 2025. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Tumor Embolization Devices Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=3352&type=smp

    Browse Through More Reports Similar to the Global Tumor Embolization Devices Market 2026, By The Business Research Company

    Neurovascular Embolization Devices Market Report 2026

    https://www.thebusinessresearchcompany.com/report/neurovascular-embolization-devices-global-market-report

    Transcatheter Embolization And Occlusion Devices Market Report 2026

    https://www.thebusinessresearchcompany.com/report/transcatheter-embolization-and-occlusion-devices-global-market-report

    Uterine Fibroid Embolization Device Market Report 2026

    https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Tumor Embolization Devices Market Outlook 2026–2035: Growth Drivers and Industry Forecast

    Tumor Embolization Devices Market Outlook 2026–2035: Growth Drivers and Industry Forecast

    Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

    What size range is anticipated for the Tumor Embolization Devices Market from 2026 to 2030?

    The market size for tumor embolization devices has experienced robust growth recently. This market is projected to expand from $1587.48 billion in 2025 to $1732.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.1%. Historically, this growth can be attributed to factors such as the broadening of interventional oncology practices, an increase in the occurrence of solid tumors, a rise in the uptake of minimally invasive procedures, the accessibility of sophisticated catheter technologies, and the expanding application of embolization within cancer treatment.

    The tumor embolization devices market is anticipated to experience substantial expansion in the coming years. It is projected to reach $2464.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. This expansion during the forecast period can be attributed to several factors, including escalating investments in interventional oncology, a heightened demand for combination cancer therapies, the broadening of targeted drug delivery techniques, an increasing emphasis on organ-sparing treatments, and the greater integration of imaging-guided interventions. Key trends anticipated within the same period encompass the growing adoption of targeted embolization therapies, a surge in demand for drug-eluting embolic agents, the expanding application of image-guided embolization procedures, the proliferation of minimally invasive oncology interventions, and an intensified focus on precise tumor targeting.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp

    What Drivers Are Affecting Demand In The Tumor Embolization Devices Market?

    The worldwide increase in cancer diagnoses is anticipated to drive the growth of the tumor embolization devices market during the forecast period. Cancer is a condition defined by the unrestrained multiplication of abnormal cells that possess the capacity to invade or spread to other bodily regions. The escalation in cancer cases is primarily influenced by aging populations, as older individuals face an elevated risk of developing cancer due to accumulated genetic mutations and extended exposure to risk factors. Tumor embolization devices are instrumental in addressing the rising cancer prevalence by offering a targeted, minimally invasive therapeutic approach that restricts blood flow to tumors, effectively impeding their growth and improving patient outcomes. For instance, in 2023, the American Cancer Society Inc., a US-based non-profit health group, documented 1,958,310 new cancer cases diagnosed in the US, marking an increase from more than 1,918,030 new cancer cases in 2022. Therefore, the escalating global cancer incidence rate is projected to significantly enhance demand for the tumor embolization market in the forthcoming years.

    Which Segments Are Gaining Traction In The Tumor Embolization Devices Market?

    The tumor embolization devices market covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    Which Trends Are Guiding The Evolution Of The Tumor Embolization Devices Market?

    Leading companies in the tumor embolization devices market are intensifying their efforts to launch innovative treatments, such as Eye90, to maximize their market revenue. Eye90 microspheres serve as a Y90 radioembolization device specifically developed for addressing liver tumors, particularly hepatocellular carcinoma. For example, in May 2023, ABK Biomedical, a medical device company based in Canada, obtained Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin a multicenter pivotal study involving Eye90 microspheres for hepatocellular carcinoma. Eye90 microspheres represent a cutting-edge Y90 radioembolization technology, produced through a proprietary manufacturing process that ensures microspheres possess a consistent size distribution and a high concentration of radioactivity. These microspheres are engineered to deliver a substantial radiation dose directly to the tumor while minimizing exposure to surrounding healthy tissue.

    Who Are The Top-Performing Companies In The Tumor Embolization Devices Market In Recent Years?

    Major companies operating in the tumor embolization devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., Varian Medical Systems Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    How Does The Tumor Embolization Devices Market Perform Across Major Global Regions?

    North America was the largest region in the tumor embolization devices market in 2025. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Tumor Embolization Devices Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=3352&type=smp

    Browse Through More Reports Similar to the Global Tumor Embolization Devices Market 2026, By The Business Research Company

    Neurovascular Embolization Devices Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/neurovascular-embolization-devices-global-market-report

    Transcatheter Embolization And Occlusion Devices Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/transcatheter-embolization-and-occlusion-devices-global-market-report

    Uterine Fibroid Embolization Device Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

  • Global Tumor Embolization Devices Market Overview: Trends Shaping Growth to 2029

    Global Tumor Embolization Devices Market Overview: Trends Shaping Growth to 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Is The Global Market Value Of The Tumor Embolization Devices Industry In 2025?

    The market valuation for tumor embolization devices has experienced substantial expansion lately, projecting an upward trajectory from $1493.6 billion in 2024 to $1587.48 billion in the subsequent year, reflecting a consistent compound annual growth rate of 6.3%; this robust expansion observed during the past period is fundamentally linked to the increasing adoption of less invasive medical operations, ongoing progress in medical technology, a higher prevalence of cancer diagnoses, and demographic shifts toward an older populace.

    The overall valuation of the tumor embolization devices sector is projected to experience a robust expansion over the coming years, reaching an estimated $2254.67 billion by 2029, reflecting a steady compound annual growth rate (CAGR) of 9.2% throughout the projection span. This upward trajectory is being fueled by advancements such as personalized medical approaches, the adoption of combination treatments, sophisticated image-guided embolization techniques, and the increasing use of telemedicine and remote consultative services. Key developments anticipated in the coming period encompass novel developments concerning embolic agents, the expanding role of transarterial chemoembolization (TACE), the utilization of embolization for alleviating patient discomfort (palliative care), and continuous refinement in image-guided procedural methods.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp

    Which Major Market Drivers Are Shaping The Future Of The Tumor Embolization Devices Market?

    A global escalation in cancer diagnoses is projected to fuel the expansion of the tumor embolization devices market throughout the predicted timeframe. To illustrate this trend, Macmillan Cancer Support, the foremost healthcare charity in the United Kingdom, provided figures in October 2022 predicting that the cancer patient population would reach 3.5 million by the year 2025, increase further to 4 million by 2030, and ultimately climb to 5.3 million by 2040; consequently, the increasing worldwide rate of cancer occurrences is expected to drive up the need for tumor embolization solutions in the years ahead.

    What Are The Major Segment Types Covered In The Tumor Embolization Devices Market?

    The tumor embolization devicesmarket covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    How Are Emerging Market Trends Shaping The Tumor Embolization Devices Industry Landscape?

    Key enterprises within the sphere of tumor embolization apparatuses are actively developing novel offerings, such as angiography instrumentation, with the goal of boosting the precision and efficacy associated with treatments focused on tumors. These angiography apparatuses serve as dedicated imaging technologies employed for mapping out vascular pathways and evaluating circulatory dynamics within the patient’s body. As an illustration, in the month of June in 2022, Siemens Healthineers, a corporation headquartered in Germany specializing in healthcare solutions, introduced the Artis Icono Ceiling; this particular angiography setup, which is mounted to the ceiling, was engineered to augment exactness during tumor embolization procedures and other minimally invasive interventions. What distinguishes the Artis Icono Ceiling is its capacity for swift acquisition of three-dimensional (3D) information, enabling image capture from the patient’s head region in a mere 2.5 seconds and from lateral angles in 4 seconds, a capability that substantially lessens image distortions caused by movement and concurrently lowers the requisite volume of contrast agents. Furthermore, the Artis Icono Ceiling has been conceived with adaptability in mind, positioning it as a suitable tool for deployment across several medical disciplines, notably interventional radiology and cardiology.

    Which Key Players Are Driving Competition In The Tumor Embolization Devices Market?

    Major companies operating in the tumor embolization devices market include Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Siemens Healthineers AG, Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Meril Life Sciences Pvt. Ltd., Kaneka Corporation, Imagion Biosystems Ltd., Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Monteris Medical Corporation, NeuWave Medical Inc., Neoprobe Corporation, OncoSec Medical Incorporated, Helomics Corporation, Hologic, Surefire Medical Inc., Varian Medical Systems Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    What Regional Growth Trends Are Shaping The Tumor Embolization Devices Market Outlook?

    North America was the largest region in the tumor embolization devices market in 2024. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Request A Customized Version Of The Tumor Embolization Devices Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=3352&type=smp

    Browse Through More Reports Similar to the Global Tumor Embolization Devices Market 2025, By The Business Research Company

    Cardiac Assist Devices And Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

    Pain Management Devices And Therapies Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

    Implantable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Tumor Embolization Devices Market Overview: Trends Shaping Growth to 2029

    Global Tumor Embolization Devices Market Overview: Trends Shaping Growth to 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Is The Global Market Value Of The Tumor Embolization Devices Industry In 2025?

    The market valuation for tumor embolization devices has experienced substantial expansion lately, projecting an upward trajectory from $1493.6 billion in 2024 to $1587.48 billion in the subsequent year, reflecting a consistent compound annual growth rate of 6.3%; this robust expansion observed during the past period is fundamentally linked to the increasing adoption of less invasive medical operations, ongoing progress in medical technology, a higher prevalence of cancer diagnoses, and demographic shifts toward an older populace.

    The overall valuation of the tumor embolization devices sector is projected to experience a robust expansion over the coming years, reaching an estimated $2254.67 billion by 2029, reflecting a steady compound annual growth rate (CAGR) of 9.2% throughout the projection span. This upward trajectory is being fueled by advancements such as personalized medical approaches, the adoption of combination treatments, sophisticated image-guided embolization techniques, and the increasing use of telemedicine and remote consultative services. Key developments anticipated in the coming period encompass novel developments concerning embolic agents, the expanding role of transarterial chemoembolization (TACE), the utilization of embolization for alleviating patient discomfort (palliative care), and continuous refinement in image-guided procedural methods.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp

    Which Major Market Drivers Are Shaping The Future Of The Tumor Embolization Devices Market?

    A global escalation in cancer diagnoses is projected to fuel the expansion of the tumor embolization devices market throughout the predicted timeframe. To illustrate this trend, Macmillan Cancer Support, the foremost healthcare charity in the United Kingdom, provided figures in October 2022 predicting that the cancer patient population would reach 3.5 million by the year 2025, increase further to 4 million by 2030, and ultimately climb to 5.3 million by 2040; consequently, the increasing worldwide rate of cancer occurrences is expected to drive up the need for tumor embolization solutions in the years ahead.

    What Are The Major Segment Types Covered In The Tumor Embolization Devices Market?

    The tumor embolization devicesmarket covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    How Are Emerging Market Trends Shaping The Tumor Embolization Devices Industry Landscape?

    Key enterprises within the sphere of tumor embolization apparatuses are actively developing novel offerings, such as angiography instrumentation, with the goal of boosting the precision and efficacy associated with treatments focused on tumors. These angiography apparatuses serve as dedicated imaging technologies employed for mapping out vascular pathways and evaluating circulatory dynamics within the patient’s body. As an illustration, in the month of June in 2022, Siemens Healthineers, a corporation headquartered in Germany specializing in healthcare solutions, introduced the Artis Icono Ceiling; this particular angiography setup, which is mounted to the ceiling, was engineered to augment exactness during tumor embolization procedures and other minimally invasive interventions. What distinguishes the Artis Icono Ceiling is its capacity for swift acquisition of three-dimensional (3D) information, enabling image capture from the patient’s head region in a mere 2.5 seconds and from lateral angles in 4 seconds, a capability that substantially lessens image distortions caused by movement and concurrently lowers the requisite volume of contrast agents. Furthermore, the Artis Icono Ceiling has been conceived with adaptability in mind, positioning it as a suitable tool for deployment across several medical disciplines, notably interventional radiology and cardiology.

    Which Key Players Are Driving Competition In The Tumor Embolization Devices Market?

    Major companies operating in the tumor embolization devices market include Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Siemens Healthineers AG, Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Meril Life Sciences Pvt. Ltd., Kaneka Corporation, Imagion Biosystems Ltd., Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Monteris Medical Corporation, NeuWave Medical Inc., Neoprobe Corporation, OncoSec Medical Incorporated, Helomics Corporation, Hologic, Surefire Medical Inc., Varian Medical Systems Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    What Regional Growth Trends Are Shaping The Tumor Embolization Devices Market Outlook?

    North America was the largest region in the tumor embolization devices market in 2024. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Request A Customized Version Of The Tumor Embolization Devices Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=3352&type=smp

    Browse Through More Reports Similar to the Global Tumor Embolization Devices Market 2025, By The Business Research Company

    Cardiac Assist Devices And Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

    Pain Management Devices And Therapies Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

    Implantable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Tumor Embolization Devices Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Tumor Embolization Devices Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Projected Market Size and Growth Rates for the Tumor Embolization Devices Market From 2025 To 2029?

    The market size for tumor embolization devices has seen significant growth in recent years. The market is expected to rise from $1493.6 billion in 2024 to around $1587.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.3%. The growth experienced in the past is attributed to factors such as the adoption of minimally invasive procedures, advancements in technology, incidence of cancer, and the aging population.

    We can anticipate a robust expansion in the market for tumor embolization devices in the forthcoming years, reaching a value of $2254.67 billion in 2029, with a compound annual growth rate (CAGR) of 9.2%. The projected growth for this period is credited to the rise in personalized medicine, combination therapies, image-guided embolization, telemedicine, and remote consultations. The upcoming trends for this forecast period would involve novel embolic agents, transarterial chemoembolization (tace), palliative care embolization, and image-guided procedures.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp

    Which Primay Drivers Are Accelerating Growth in the Tumor Embolization Devices Market?

    The global increase in cancer cases is expected to fuel the expansion of the tumor embolization devices market in the upcoming years. For instance, Macmillan Cancer Support, the leading healthcare charity in the UK, projected in October 2022 that by 2025, the number of cancer patients will reach 3.5 million, growing to 4 million by 2030, and 5.3 million by 2040. Thus, the escalating incidence of cancer worldwide is predicted to stimulate the demand for the tumor embolization market in the foreseeable future.

    Which Primary Segments of the Tumor Embolization Devices Market Are Driving Growth and Industry Transformations?

    The tumor embolization devicesmarket covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=3352&type=smp

    Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Tumor Embolization Devices Market?# Market?

    North America was the largest region in the tumor embolization devices market in 2024. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Which Technological Trends Are Reshaping the Tumor Embolization Devices Industry Dynamics?

    Key players in the tumor embolization devices market are stepping up their game by developing products such as angiography systems that can amplify the precision and efficiency of treatments aimed at tumors. These systems are advanced imaging devices that enable physicians to see blood vessels and monitor blood circulation within the body. Take for instance Siemens Healthineers, a healthcare firm based in Germany. In June 2022, it introduced the Artis Icono Ceiling, a ceiling-mounted angiography system crafted to elevate the level of precision in tumor embolization and multiple interventional procedures. The Artis Icono Ceiling can rapidly acquire three-dimensional (3D) data, able to capture images at the patient’s head in a mere 2.5 seconds, and from the sides in 4 seconds. Its design reduces motion disturbances and decreases the requirement for contrast media. Versatility is weaved into the Artis Icono Ceiling’s design, making it adaptable for use in a range of specialties, not limited to interventional radiology and cardiology.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    What Parameters Are Used to Define the Tumor Embolization Devices Market?

    Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3352

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Tumor Embolization Devices Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Tumor Embolization Devices Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Projected Market Size and Growth Rates for the Tumor Embolization Devices Market From 2025 To 2029?

    The market size for tumor embolization devices has seen significant growth in recent years. The market is expected to rise from $1493.6 billion in 2024 to around $1587.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.3%. The growth experienced in the past is attributed to factors such as the adoption of minimally invasive procedures, advancements in technology, incidence of cancer, and the aging population.

    We can anticipate a robust expansion in the market for tumor embolization devices in the forthcoming years, reaching a value of $2254.67 billion in 2029, with a compound annual growth rate (CAGR) of 9.2%. The projected growth for this period is credited to the rise in personalized medicine, combination therapies, image-guided embolization, telemedicine, and remote consultations. The upcoming trends for this forecast period would involve novel embolic agents, transarterial chemoembolization (tace), palliative care embolization, and image-guided procedures.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp

    Which Primay Drivers Are Accelerating Growth in the Tumor Embolization Devices Market?

    The global increase in cancer cases is expected to fuel the expansion of the tumor embolization devices market in the upcoming years. For instance, Macmillan Cancer Support, the leading healthcare charity in the UK, projected in October 2022 that by 2025, the number of cancer patients will reach 3.5 million, growing to 4 million by 2030, and 5.3 million by 2040. Thus, the escalating incidence of cancer worldwide is predicted to stimulate the demand for the tumor embolization market in the foreseeable future.

    Which Primary Segments of the Tumor Embolization Devices Market Are Driving Growth and Industry Transformations?

    The tumor embolization devicesmarket covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=3352&type=smp

    Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Tumor Embolization Devices Market?# Market?

    North America was the largest region in the tumor embolization devices market in 2024. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Which Technological Trends Are Reshaping the Tumor Embolization Devices Industry Dynamics?

    Key players in the tumor embolization devices market are stepping up their game by developing products such as angiography systems that can amplify the precision and efficiency of treatments aimed at tumors. These systems are advanced imaging devices that enable physicians to see blood vessels and monitor blood circulation within the body. Take for instance Siemens Healthineers, a healthcare firm based in Germany. In June 2022, it introduced the Artis Icono Ceiling, a ceiling-mounted angiography system crafted to elevate the level of precision in tumor embolization and multiple interventional procedures. The Artis Icono Ceiling can rapidly acquire three-dimensional (3D) data, able to capture images at the patient’s head in a mere 2.5 seconds, and from the sides in 4 seconds. Its design reduces motion disturbances and decreases the requirement for contrast media. Versatility is weaved into the Artis Icono Ceiling’s design, making it adaptable for use in a range of specialties, not limited to interventional radiology and cardiology.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    What Parameters Are Used to Define the Tumor Embolization Devices Market?

    Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3352

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Market Analysis on Tumor Embolization Devices Industry – Insights for Corporate Strategy and R&D

    Market Analysis on Tumor Embolization Devices Industry – Insights for Corporate Strategy and R&D

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Projected Market Size and Growth Rates for the Tumor Embolization Devices Market From 2025 To 2029?

    In recent times, we’ve seen significant growth in the tumor embolization devices market. It’s projected to expand from $1493.6 billion in 2024 to a staggering $1600.57 billion in 2025, representing a compound annual growth rate (CAGR) of 7.2%. Factors such as minimally invasive procedures, technological progress, cancer prevalence, and an aging population are the driving forces behind the growth experienced in the historical period.

    What Is the Projected Market Size of the Tumor Embolization Devices Market?

    The market for tumor embolization devices is predicted to witness robust expansion in the forthcoming years. It is projected to reach a value of $2286.1 billion by 2029, increasing at a compound annual growth rate (CAGR) of 9.3%. This uptrend during the estimated period can be credited to factors such as personalized healthcare, hybrid therapies, image-led embolization, telemedicine, and distant consultations. Key developments anticipated during this period encompass breakthroughs in embolic agents, transarterial chemoembolization (tace), embolization for effective palliative care, and image-directed operations.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp

    Who are the Major Competitors in the Tumor Embolization Devices Market Outlook?

    Major companies operating in the tumor embolization devices market include Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Siemens Healthineers AG, Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Meril Life Sciences Pvt. Ltd., Kaneka Corporation, Imagion Biosystems Ltd., Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Monteris Medical Corporation, NeuWave Medical Inc., Neoprobe Corporation, OncoSec Medical Incorporated, Helomics Corporation, Hologic, Surefire Medical Inc., Varian Medical Systems Inc.

    What Is Fueling Growth in the Tumor Embolization Devices Market?

    The global increase in cancer cases is expected to spur the expansion of the tumor embolization devices market in the projected timeline. To illustrate, Macmillan Cancer Support, a leading healthcare charity organization in the UK, predicted in October 2022 that by 2025, 3.5 million people would have cancer, 4 million by 2030, and by 2040, the number is projected to reach 5.3 million. As a result, the escalating rate of cancer globally will likely heighten the demand for the tumor embolization market in the coming years.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=3352&type=smp

    Which Tumor Embolization Devices Market Segments Are Growing the Fastest?

    The tumor embolization devices market covered in this report is segmented –

    1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents

    2) By Application: Cancer Tumors, Noncancerous Tumors

    3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

    Subsegments:

    1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres

    2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol – PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

    Which Industry Trends Are Shaping the Future of the Tumor Embolization Devices Market?

    Leading firms in the tumor embolization devices market are introducing innovations such as angiography systems to improve the precision and efficacy of treatments targeting tumors. Angiography systems are advanced imaging devices that provide a visualization of blood vessels and measure blood flow within the body. For example, Siemens Healthineers, a healthcare company based in Germany, unveiled the Artis Icono Ceiling in June 2022. This is an angiography system attached to the ceiling setup, developed specifically to enhance accuracy in tumor embolization and other similar procedures. The Artis Icono Ceiling has the feature of fast 3D data acquisition, able to take images at the patient’s head in a mere 2.5 seconds, and from the sides in 4 seconds. This lessens motion distortions and lowers the dependence on contrast media. The design of the Artis Icono Ceiling offers adaptability, making it usable across different disciplines, such as interventional radiology and cardiology.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    Which Countries Are Leading the Tumor Embolization Devices Market?

    North America was the largest region in the tumor embolization devices market in 2023. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3352

    This Report Delivers Insight On:

    1. How big is the tumor embolization devices market, and how is it changing globally?

    2. Who are the major companies in the tumor embolization devices market, and how are they performing?

    3. What are the key opportunities and risks in the tumor embolization devices market right now?

    4. Which products or customer segments are growing the most in the tumor embolization devices market?

    5. What factors are helping or slowing down the growth of the tumor embolization devices market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model